Hematopoietic and Lymphoid Cell Neoplasm
Associated Genetic Biomarkers
NCI Definition: A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes. 
There are 2 clinical trials for hematopoietic and lymphoid cell neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain hematopoietic and lymphoid cell neoplasm as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
FGFR1 is the most frequent gene inclusion criterion for hematopoietic and lymphoid cell neoplasm clinical trials .
Atezolizumab and pemigatinib are the most common interventions in hematopoietic and lymphoid cell neoplasm clinical trials.
Significant Genes in Hematopoietic and Lymphoid Cell Neoplasm
FGFR1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and hematopoietic and lymphoid cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.